Dr. Reddy's Laboratories Limited
NYSE:RDYDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $12.48B
- Beta
- 0.26
- P/E (TTM)
- 24.7
- EPS (TTM)
- $51.40
- Dividend yield
- 0.63%
Volume 1.79M
Average 2.39M
RDY Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Dr. Reddy's Laboratories LimitedNYSE: RDY
Selling, General & Admin · Q2 FY2027 · quarter ended Sep 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2027 selling, general & admin of ₹28.04B rose 6.1% year over year, behind the +14.7% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at +18.2% a year.
Context
- Selling, general & admin amounted to 31.8% of revenue in FY2026, up 2.9 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 18 analysts of ₹102.97B (-8.3%) for the fiscal year ending Mar 2027, a slowdown from the +19.7% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- ₹28.04B-3.3% QoQ
- Last fiscal yearMar 2026
- ₹112.34B+19.7% YoY
- LTMSep 2026
- ₹112.14B+14.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
INR · from the income statement
- Latest · FY2026
- 112.34B INR
- Year-over-year change
- +19.7%
- 4-year CAGR
- +16.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 112.34B | +19.7% |
| FY2025 | 2025-03-31 | 93.87B | +21.6% |
| FY2024 | 2024-03-31 | 77.2B | +13.5% |
| FY2023 | 2023-03-31 | 68.03B | +9.6% |
| FY2022 | 2022-03-31 | 62.08B | — |
Selling, General & Admin vs competitors
How RDY compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.7% is the 3rd highest of 7, against a peer median of +11.6%.
- Selling, general & admin amounts to 33.8% of revenue for RDY, versus a peer median of 27.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹112.14B INR | +14.7% | +18.2% | 33.8% | |
| LTM Jun 2025 | £6.42B GBP | — | +2.6% | 38.8% | |
| LTM Jun 2026 | $4.13B USD | +9.9% | +4.9% | 23.8% | |
| LTM Jun 2026 | $3.98B USD | +1.3% | -3.2% | 27.0% | |
| LTM Jun 2026 | $3.45B USD | +0.5% | +10.7% | 31.7% | |
| LTM Jun 2026 | $571.86M USD | +16.7% | +9.6% | 18.3% | |
| LTM Mar 2026 | $314.87M USD | +13.2% | +36.8% | 34.1% | |
| LTM Mar 2026 | $131.9M USD | +35.5% | +24.9% | 18.3% | |
| Peer median (excluding RDY) | — | +11.6% | +9.6% | 27.0% | |
Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 214.39B | 245.88B | 279.16B | 325.54B | 353.47B |
| Cost of Revenue | 100.55B | 106.54B | 115.56B | 135.11B | 166.95B |
| Gross Profit | 113.84B | 139.34B | 163.61B | 190.43B | 186.52B |
| Gross Margin | 53.1% | 56.7% | 58.6% | 58.5% | 52.8% |
| Research & Development | 17.48B | 19.38B | 22.87B | 27.38B | 25.31B |
| Selling, General & Admin | 62.08B | 68.03B | 77.2B | 93.87B | 112.34B |
| Operating Expenses | 84.36B | 82.2B | 95.88B | 118.59B | 137.65B |
| Depreciation & Amortization | 11.82B | 12.64B | 14.84B | 17.06B | 21.68B |
| EBITDA | 45.08B | 74.43B | 88.42B | 96.67B | 83.29B |
| EBITDA Margin | 21.0% | 30.3% | 31.7% | 29.7% | 23.6% |
| Operating Income | 29.48B | 57.14B | 67.73B | 71.84B | 48.87B |
| Operating Margin | 13.7% | 23.2% | 24.3% | 22.1% | 13.8% |
| Interest Income | 965M | 1.18B | 2.28B | 2.68B | 8.28B |
| Interest Expense | 958M | 1.43B | 1.71B | 2.83B | 3.93B |
| Other Income / Expenses | 2.82B | 3.22B | 4.14B | 4.94B | 8.81B |
| Income Before Tax | 32.3B | 60.37B | 71.87B | 76.78B | 57.68B |
| Pre-Tax Margin | 15.1% | 24.6% | 25.7% | 23.6% | 16.3% |
| Income Tax Expense | 8.73B | 15.3B | 16.19B | 19.54B | 13B |
| Net Income | 23.57B | 45.07B | 55.68B | 56.54B | 45.09B |
| Net Margin | 11.0% | 18.3% | 19.9% | 17.4% | 12.8% |
| EPS (Basic) | 28.42 | 54.29 | 66.80 | 67.85 | 53.92 |
| EPS (Diluted) | 28.34 | 54.17 | 66.80 | 67.77 | 53.92 |
| Weighted Avg Shares | 829.41M | 830.17M | 833.54M | 833.31M | 832.41M |
| Weighted Avg Shares (Diluted) | 831.69M | 831.91M | 833.54M | 834.3M | 833.26M |
Dr. Reddy's Laboratories Limited
NYSE:RDY
Intrinsic Alpha fair value
Locked
Current Price
$14.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.